Travis Barr Email & Phone Number

Arlington, Ma, Us

Rahway, New Jersey, Us

Cambridge, Ma, Us

• Led in vitro and in vivo preclinical activities for ACE-1334 program (Ph1b/2) in lung and skin fibrosis with a team of 1-2 direct reports and constant support from other teams• Developed and validated in vivo models (mouse, rat, monkey) and endpoint analyses (qPCR/Nanostring, Western Blot, ELISA/MSD, Biochemical assays, histology/immunohistochemistry with pathological scoring/quantitative image analysis)• Hands-on experience with mouse/rat dosing (s.c., i.p., p.o), tissue collection and survival surgery, as well as study planning and in vivo model transfer to CROs• Worked closely with Non-clinical, Translational and Clinical Teams to support PK/PD, target engagement assessment, biomarker identification/assay validation and clinical trial planning (e.g. dose-selection and sample analysis)• Responsible for representing the project at cross-functional meetings and writing regulatory technical reports for IND submission and IB updates• Established relationships with external CROs for in vivo models, transgenic mouse colonies and endpoint analyses (histology/gene expression analysis)• Worked with Non-clinical and external consultants to set up in-house and external inhalation dosing capabilities to assess PK, tolerability, target engagement and PD• Utilized in vitro cell-based and ex vivo (precision cut tissue slices) models of fibrosis• Team ACE Award recipient (2020) and company pool champion (2019)

Cambridge, Ma, Us

Cambridge, Ma, Us

Boston, Ma, Us

• Developing peptide inhibitors of PAR2 for treatment of inflammatory and fibrotic diseases in collaboration with Oasis Pharmaceuticals and Tufts Medical Center.• Optimized and conducted FLIPR, carrageenan-induced inflammation, MCD diet and CCL4-induced liver fibrosis experiments to guide SAR leading to NASH development candidate selection and on-going IND-enabling studies.• Lead planning and collection of preliminary data for STTR grant submission to fund IND-enabling studies for idiopathic pulmonary fibrosis. This involved performing and overseeing FACS, qPCR, ELISA and histology of bleomycin-induced IPF in mice.• Developed and utilized qPCR-based assays of human keratinocytes and mast cells as in vitro models of atopic dermatitis for proof of concept and target validation studies.• Using oxazolone-induced ear edema, mastoparan-evoked itch and dust mite-treated flaky tail mice as in vivo models of atopic dermatitis for IND-enabling efficacy studies.• Managing CROs to test penetration and efficacy of topicals for atopic dermatitis.• Developing a neutrophil-based pharmacodynamic assay for use in NASH clinical trials.• Assessed acute toxicity of test compounds in mice and rats.• Performed statistical analyses of Phase I clinical data for FDA submission.

Us

• Investigated endothelin (ET-1) signaling in keratinocytes and its role in peripheral pain.• Used qPCR, Ca++ imaging and western blot to characterize endothelin receptor expression and pathways in a variety of cell types (e.g. keratinocytes, sensory neurons). • Utilized qPCR, Ca++ imaging and pharmacological tools to identify a neuronal ATP receptor sensitized by endothelin receptor activation with a role in post-surgical pain.• Used Ca++ imaging to analyze effect of local anesthetics on GPCR function (e.g. ET-1).• Performed western blots to analyze changes in MAPK in spinal cords of mice given thoracotomy surgery with ablation of NK-1 expressing neurons.• Oversaw radioligand binding experiments analyzing GPCR dimer interactions.

Albany, Ny, Us

• Investigated changes in the peripheral nervous system underlying chronic pain conditions, with a focus on the role of keratinocyte-nerve interactions.• Used IHC to analyze changes in cutaneous protein expression in human patients (e.g. post-herpetic neuralgia) and mouse models (pain/transgenics). Characterized and quantified structures including nerves, vasculature, epidermis and sweat glands.• Identified a novel ATP release mechanism in keratinocytes using qPCR and cell-based assays that likely contributes to both epidermal homeostasis and chronic pain.• Utilized radioligand binding and GTPyS autoradiography to analyze antagonism and allosteric modulation of GPCRs by novel compounds.• Measured brain dopamine levels using in vivo microdialysis with HPLC analysis.

Shippensburg, Pa, Us

• Assessed differences in brain lateralization in undergraduate binge drinkers using questionnaires in combination with odor presentation to measure olfactory perception.• Measured deficits in reversal learning following binge ethanol exposure in mice using radial arm and elevated plus mazes.• Tutored and co-mentored undergraduates in coursework and research.• Maintained psychology department animal facility (bedding changes, feeding, etc)

Doctor Of Philosophy (Phd), Neuropharmacology And Neuroscience

Master Of Science (Ms), Psychology

Bachelor Of Science (Bs), Psychobiology